Journal Logo

Simultaneous Sessions III: Novel agents for newly diagnosed plasma cell dyscrasias

S872 CARFILZOMIB LENALIDOMIDE DEXAMETHASONE (KRD) WITH OR WITHOUT TRANSPLANTATION IN NEWLY DIAGNOSED MYELOMA (FORTE TRIAL): EFFICACY ACCORDING TO RISK STATUS

Gay, F.1; Cerrato, C.1; Rota Scalabrini, D.1; Belotti, A.1; Galli, M.1; Zamagni, E.1; Offidani, M.1; Omedé, P.1; Monaco, F.1; Tosi, P.1; Annibali, O.1; Pisani, F.1; Troia, R.1; Pascarella, A.1; Ferrara, F.1; Cea, M.1; Dalla Palma, B.1; Patriarca, F.1; Aquino, S.1; Palmas, A.1; Siniscalchi, A.1; Grasso, M.1; Palumbo, A.2; Ledda, A.1; Musto, P.1; Cavo, M.1; Boccadoro, M.1

Author Information
doi: 10.1097/01.HS9.0000561768.53887.ff
  • Free

Abstract

Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association.